A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia
Go back to A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1102.08 +3.51 (0.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1098.57 | 52 Week High | $88.16 | |||
| Open | $1112.24 | 52 Week Low | $67.88 | |||
| Day High | $1119.45 | P/E | 255.11 | |||
| Day Low | $1093.15 | EPS | $4.32 | |||
| Volume | 3,013,388 | |||||
